Kyntra BioLTS:0IL8 -1.94%50 PEG Ratio is 0.00 as of Jul. 09, 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $5.70 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 94 Biotechnology companies, Kyntra Bio ranks worse than 1063828.72% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Kyntra Bio's PE Ratio without NRI is 0.00. Kyntra Bio's 5-Year EBITDA growth rate is 22.30%. Therefore, Kyntra Bio's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Kyntra Bio's PEG Ratio or its related term are showing as below:
LTS:0IL8's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.98 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Kyntra Bio (LTS:0IL8) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Kyntra Bio PEG Ratio Related Terms
Kyntra Bio PEG Ratio Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs TVGN, PSTV, GRDX: PEG Ratio Comparison
For the Biotechnology subindustry, Kyntra Bio's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Kyntra Bio (LTS:0IL8) has a PEG Ratio of 0.00 as of Jul. 09, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #999999 out of 94 companies in the Biotechnology industry.
Is Kyntra Bio's PEG Ratio too high?
Kyntra Bio's current PEG Ratio is 0.00. Based on the distribution chart, Kyntra Bio ranks #999999 out of 94 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's PEG Ratio compare to TVGN and PSTV?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #999999 out of 94 companies for PEG Ratio. This places Kyntra Bio in the lower half of its industry. The industry median PEG Ratio is 1.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.98, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Kyntra Bio and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyntra Bio's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.70, compared to a current price of $7.45 — trading 30.8% above its estimated fair value. The current PEG Ratio is 0.00. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current PEG Ratio is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70.
GuruFocus considers Kyntra Bio to be Significantly Overvalued.
Key valuation signals for LTS:0IL8:
PEG Ratio: 0.00
GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score
Get the complete analysis for LTS:0IL8
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
